Table 3.
Determine and compare the validity of self-reported substance use in Rafsanjan Youth Cohort Study and primary health care setting (N = 1007)
| Rafsanjan Youth Cohort Study (research setting) | primary health care setting | compare the validity of self-reported substance use in two settings | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug/gender | Sensitivity | 95% CI | Specificitya | 95% CI | Conditional κ | 95% CI | Sensitivity | 95% CI | Specificitya | 95% CI | Conditional κ | 95% CI | p-valuec |
| opioid /total | |||||||||||||
| past 72 h | 39.4 | (22.9–57.9) | 100 | (99.4–100) | 0.381 | (0.376–0.385) | 50 | (32.4–67.6) | 100 | (99–100) | 0.478 | (0.470–0.486) | 0.383 |
| past 12 months | 57.6 | (39.2–74.5) | – | – | 0.523 | (0.522–0.524) | 64.7 | (46.5–80.3) | – | – | 0.614 | (0.608–0.620) | -d |
| opioid /men | |||||||||||||
| past 72 h | 37.5 | (21.1–56.3) | 100 | (99.2–100) | 0.360 | (0.353–0.366) | 53.3 | (34.3–71.7) | 100 | (98.2–100) | 0.498 | (0.482–0.515) | 0.211 |
| past 12 months | 56.3 | (37.7–73.6) | – | – | 0.501 | (0.499–0.503) | 70 | (50.6–85.3) | – | – | 0.651 | (0.640–0.660) | -d |
| opioid /women | |||||||||||||
| past 72 h | 100 | (2.5–100) | 100 | (96.8–100) | 1 | 1 | 25 | (.63–80.6) | 100 | (97.8–100) | 0.246 | (0.242–0.250) | 0.171 |
| past 12 months | 100 | (2.5–100) | – | – | 1 | 1 | 25 | (.63–80.6) | – | – | -d | ||
| Cannabis/men | |||||||||||||
| past 72 h | 10 | (.253–44.5) | 100 | (99.4–100) | 0.10 | (0.096–0.101) | 12.5 | (1.55–38.3) | 100 | (98.3–100) | 0.117 | (0.105–0.130) | 0.846 |
| past 12 months | 20 | (2.52–55.6) | – | – | 0.187 | (0185–0.189) | 12.5 | (1.55–38.3) | – | – | 0.105 | (0.094–0.117) | -d |
| Methadone/total | |||||||||||||
| past 72 h | 20 | (5.73–43.7) | 100 | (99.4–100) | 0.195 | (0.192–0.198) | 20.7 | (7.99–39.7) | 100 | (99–100) | 0.199 | (0.190–0.208) | 0.953 |
| past 12 months | 40 | (19.1–63.9) | – | – | 0.384 | (0.381–.0386) | 31 | (15.3–50.8) | – | – | 0.291 | (0.283–0.299) | -d |
| Methadone/men | |||||||||||||
| past 72 h | 21.1 | (6.05–45.6) | 100 | (99.2–100) | 0.210 | (0.199–0.208) | 24 | (9.36–45.1) | 100 | (98.2–100) | 0.220 | (0.202–0.237) | 0.817 |
| past 12 months | 42.1 | (20.3–66.5) | 0.402 | (0.399–0.405) | 36 | (18–57.5) | – | – | 0.327706 | (0.312–0.343) | -d | ||
| Methadone/women | |||||||||||||
| past 72 h | 0.000 | -b | 100 | – | 0.00 | – | 0.00 | – | 100 | – | 0.00 | – | – |
| past 12 months | 0.000 | -b | – | – | 0.00 | – | 0.00 | – | – | – | 0.00 | – | – |
| amphetamine and Methamphetamine/men | |||||||||||||
| past 72 h | 0.000 | -b | 100 | – | 0.00 | – | 0.00 | – | 100 | – | 0.00 | – | – |
| past 12 months | 0.000 | -b | – | – | 0.00 | – | 0.00 | – | – | – | 0.00 | – | – |
a Specificity was not calculated for past-12-month use because of the potential for inflated false negatives
b Confidence interval could not be calculated because sensitivity was zero
cChi-Square test: Comparison of self-reported substance use in two settings among urinalysis-confirmed users
dp-value was not calculated to compare of self-reported substance use over the past year, as some people may have correctly self-report of substance use over the past year, but a urine test could not determine substance use over the past year